Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myconostica raises more capital for fungal disease tests

This article was originally published in Clinica

Executive Summary

UK diagnostic company Myconostica has secured additional series D financing from its German distributor medac Gesellschaft fuer klinische Spezialpraeparate. The investment, of which the amount was undisclosed, will be used to further develop Myconostica's pipeline of fungal infection tests. medac is a privately-held Hamburg-based company with both pharma and diagnostic interests. It is the exclusive distributor of Myconostica's products in Germany. As part of the financing, Dr Rainer Dickhardt, medac's managing director, joins the board of directors at Manchester-based Myconostica.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT095172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel